Safety and efficacy of treatment with once daily ledipasvir/sofobuvir (90/400 mg) for 12 weeks in genotype 1 HCV infected patients with severe renal impairment | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Safety and efficacy of treatment with once daily ledipasvir/sofobuvir (90/400 mg) for 12 weeks in genotype 1 HCV infected patients with severe renal impairment

Lawitz E, Landis C, Maliakkal B, et al. Safety and efficacy of treatment with once daily ledipasvir/sofobuvir (90/400 mg) for 12 weeks in genotype 1 HCV infected patients with severe renal impairment. The Liver Meeting. Boston, MA; 2017.

Publication Type:

Conference Proceedings

Authors:

Lawitz, E; Landis, C; Maliakkal, B; et, al

Source:

The Liver Meeting, Boston, MA (2017)

Cited On:

Export Citation:

RIS Format

Top